Abstract
MO38-2 Post-marketing surveillance of tepotinib for non-small cell lung cancer with MET exon 14 skipping mutations – final report
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1016/j.annonc.2023.09.251
Publication Date: Nov 1, 2023 |
MO38-2 Post-marketing surveillance of tepotinib for non-small cell lung cancer with MET exon 14 skipping mutations – final report
Join us for a 30 min session where you can share your feedback and ask us any queries you have